LOS ANGELES, July 6, 2015 /PRNewswire/ -- Pharmaco-Kinesis Corporation (PKC) announced today that Andrew E. Sloan, MD has joined its Neuro-Oncology Clinical Advisory Board (NOCAB). The Company's world renowned NOCAB serves to proffer medical guidance and insight as the Company advances its Metronomic Biofeedback Pump (MBP) towards human clinical trial investigations and the commercial market. The MBP is a fully implantable, smart infusion device designed to locally deliver chemotherapy over time to a target site of the human body with biofeedback response.
Dr. Sloan is the Peter D Cristal Chair of Neurological Oncology and Director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center in Cleveland, OH, and Professor, and Vice-Chair, Department of Neurological Surgery at the Case Western Reserve University School of Medicine. Dr. Sloan is a graduate of Harvard Medical School and performed his residency in Neurological surgery at UCLA School of Medicine, followed by a Fellowship in Neurosurgical Oncology at the MD Anderson Cancer Center. His clinical interests include brain tumors, convection enhanced delivery, gamma knife and cyber-knife stereotactic radiosurgery, image guided neurosurgery, neurosurgery, skull base surgery, stereotactic surgery and tumor immunotherapy.
Dr. Thomas C. Chen, Professor of Neurological Surgery and Pathology, Keck School of Medicine, University of Southern California, and PKC's Chief Neuro-Oncology Officer chairs the NOCAB. The NOCAB recently convened in Santa Monica where Dr. Sloan was an invited guest before formerly joining the NOCAB. "We welcome Dr. Andrew Sloan to our clinical advisory board. Dr. Sloan is an accomplished neurosurgeon with expertise in the design and conduct of clinical trials for brain tumors and helped to initiate the Ohio Clinical Trials Collaborative which we anticipate will participate in MBP clinical trials," said Dr. Chen.
Current regimens for treatment of brain cancer often do not significantly improve length or quality of a patient's life. PKC intends to change this paradigm through a Smart Drug Delivery System™ (SDDS) technology, which is designed to provide physicians with a new modality to approach this devastating disease. The MBP will incorporate unique features in therapeutic delivery such as the ability to continuously sample drug concentration, maintain therapeutic levels over extended periods, monitor half life of drug and change dose regiment, all remotely from a physician's hand-held tablet or computer. By contrast, a current method of chemotherapy treatment for brain cancer embodies twice-weekly injections of relatively large quantities of the chemotherapeutic agent causing spikes of drug in the brain. Such high levels of drug cause unwanted side effects for the patient and diminished quality of life. To overcome this challenge, the MBP is designed to deliver a metered dose (metronomic delivery) of drug to the brain over the duration of the treatment. This strategy seeks to minimize the peak chemo-toxicity level while increasing the duration over which drug levels remain therapeutic. PKC plans to evaluate the effectiveness of this strategy in an upcoming clinical trial in patients diagnosed with leptomeningeal carcinomatosis and who have also had HER2 positive breast cancer.
Said Frank Adell, "We are truly honored to have Dr. Sloan's participation on our NOCAB. Through the invaluable insight of our NOCAB members, the local, metronomic delivery and biofeedback features of our MBP device are now poised to provide physicians with an unprecedented fourth modality for treatment of neurological cancer that will hopefully enhance duration and quality of life for patients by maintaining a therapeutic dose over extended periods and reducing unwanted chemo-toxicity. The invaluable feedback and insight from this group of distinguished key opinion leaders will undoubtedly make the MBP a revolutionary success for the treatment of brain cancer."
About Pharmaco-Kinesis Corporation
PKC is at pre commercialized stage high technology medical device company that aims to optimize healing of the human body through proprietary local Smart Drug Delivery Systems™ (SDDS) and associated advanced devices to measure biological responses. Its novel carbon nanotube biosensor platform culminated in PKC winning the prestigious Frost & Sullivan Award in both 2013 and 2014 and 2015. For more information, please go to http://www.pharmaco-kinesis.com/.
This news release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the management of Pharmaco-Kinesis Corporation and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/andrew-e-sloan-md-joins-pharmaco-kinesis-corporations-neuro-oncology-clinical-advisory-board-300108860.html
SOURCE Pharmaco-Kinesis Corporation